Introduction {#Sec1}
============

Severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is the virus that caused the global pandemic that was first reported \[[@CR1]\] on December 31, 2019 \[[@CR2]\]. Taxonomically, SARS CoV-2 belongs to the realm *Riboviria*, order *Nidovirales*, suborder *Cornidovirineae*, family *Coronaviridae*, subfamily *Orthocoronavirinae*, genus *Betacoronavirus* (lineage B), \[[@CR3]\] subgenus *Sarbecovirus*, and the species *Severe acute respiratory syndrome-related coronavirus*.

The genome of SARS CoV-2 (NCBI Reference Sequence: NC_045512.2) \[[@CR4]\] is similar to the genome of the coronavirus that caused the SARS epidemic in 2003 (SARS CoV, NCBI Reference sequence: NC_004718.3) \[[@CR5], [@CR6]\]. Much of the understanding of the proteins found in SARS CoV-2 are based on the numerous research studies reported on SARS CoV and other related viruses (e.g. MERS CoV) \[[@CR7], [@CR8]\]. However, among the recent coronavirus outbreaks in the new millennium (SARS CoV: 2002--2003, MERS CoV: 2012, SARS CoV-2: 2020), SARS CoV-2 mysteriously had the most devastating global impact. Understanding the proteins present in these viruses enable a more rational approach to designing more effective antiviral drugs \[[@CR9], [@CR10]\]. The majority of proteins of SARS CoV have been characterized in detail. The proteins of SARS CoV consist of two large polyproteins: ORF1a and ORF1ab (that proteolytically cleave to form 16 nonstructural proteins), four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), and eight accessory proteins: ORF3a, ORF3b (NP_828853.1, not present in SARS CoV-2), ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b (NP_828859.1, not present in SARS CoV-2). Although accessory proteins have been viewed as dispensable for viral replication in vitro, some have been shown to play an important role in virus-host interactions in vivo \[[@CR11]\]. Similar to SARS CoV, SARS CoV-2 lacks the hemagglutinin esterase gene, which is found in human coronavirus (hCoV) HKU1, a lineage A betacoronavirus \[[@CR3]\]. The spike protein, envelope protein, membrane protein, nucleocapsid protein, 3CL protease, papain like protease, RNA polymerase, \[[@CR10]\] and helicase protein have been suggested to be viable antiviral drug targets \[[@CR12]\]. SARS CoV-2 is an RNA virus and its RNA genome is 30 kb in length. SARS CoV-2 is thought to have originated from its closest relative, BatCov RaTG13 (GenBank: MN996532), \[[@CR13]\] which was isolated from horseshoe bats \[[@CR14]\].

Discussion: Proteins of SARS CoV-2 {#Sec2}
==================================

SARS CoV-2 (NC_045512.2) has a total of 11 genes with 11 open reading frames (ORFs) (Table [1](#Tab1){ref-type="table"}): ORF1ab, ORF2 (Spike protein), ORF3a, ORF4 (Envelope protein), ORF5 (Membrane protein), ORF6, ORF7a, ORF7b, ORF8, ORF9 (Nucleocapsid protein), and ORF10.Table 1The genes expressed by SARS CoV-2 (NC_045512.2)Number(\#)GeneGeneIDLocationProtein\[LOCUS\]1(7,096)ORF1ab43,740,578266--21,555ORF1ab polyprotein\[BCB15089.1/BCB97900.1\]1(4,405)ORF1a43,740,578266--13,483ORF1a polyprotein\[YP_009725295.1\]2(1,273)ORF2 (S)43,740,56821,563--25,384Spike protein (S protein)\[BCA87361.1\]3(275)ORF3a43,740,56925,393--26,220ORF3a protein\[BCA87362.1\]4(75)ORF4 (E)43,740,57026,245--26,472Envelope protein (E protein)\[BCA87363.1\]5(222)ORF5 (M)43,740,57126,523--27,191Membrane protein (M protein)\[BCA87364.1\]6(61)ORF643,740,57227,202--27,387ORF6 protein\[BCA87365.1\]7(121)ORF7a43,740,57327,394--27,759ORF7a protein\[BCA87366.1\]8(43)ORF7b43,740,57427,756--27,887ORF7b protein\[BCB15096.1\]9(121)ORF843,740,57727,894--28,259ORF8 protein\[BCA87367.1\]10(419)ORF9 (N)43,740,57528,274--29,533Nucleocapsid phosphoprotein (N protein)\[BCA87368.1\]11(38)ORF1043,740,57629,558--29,674ORF10 protein\[BCA87369.1\]\#Represents the number of amino acids in each gene

Polyprotein Expressed by ORF1ab {#Sec3}
-------------------------------

The first gene (ORF1ab) expresses a polyprotein. The ORF1ab polyprotein is comprised of 16 nonstructural proteins (NSPs) (Table [2](#Tab2){ref-type="table"}).Table 2The nonstructural proteins (NSPs) found in the polyprotein of SARS CoV-2\#NameAccessionAmino acidsProposed function(i)NSP1YP_009725297.1180 amino acidsInduce host mRNA (leader protein) cleavage(ii)NSP2YP_009725298.1638 amino acidsBinds to PHBs 1, 2(iii)NSP3^a^YP_009725299.11945 amino acidsRelease NSPs 1, 2, 3(Papain like proteinase)(iv)NSP4YP_009725300.1500 amino acidsMembrane rearrangement(v)NSP5^a^YP_009725301.1306 amino acidsCleaves at 11 sites of (3C-like proteinase) NSP polyprotein(vi)NSP6YP_009725302.1290 amino acidsGenerates autophagosomes(vii)NSP7YP_009725303.183 amino acidsDimerizes with NSP8(viii)NSP8YP_009725304.1198 amino acidsStimulates NSP12(ix)NSP9YP_009725305.1113 amino acidsBinds to helicase(?)(x)NSP10YP_009725306.1139 amino acidsStimulates NSP16(?)(xi)NSP11YP_009725312.113 amino acidsUnknown(xii)NSP12^a^YP_009725307.1932 amino acidsCopies viral RNA (RNA polymerase) methylation (guanine)(xiii)NSP13YP_009725308.1601 amino acidsUnwinds duplex RNA (Helicase)(xiv)NSP14YP_009725309.1527 amino acids5′-cap RNA (3′ to 5′ exonuclease, guanine N7-methyltransferase)(xv)NSP15^a^YP_009725310.1346 amino acidsDegrade RNA to (endoRNAse/endoribonuclease) evade host defense(xvi)NSP16YP_009725311.1298 amino acids5′-cap RNA (2′-O-ribose-methyltransferase---potential antiviral drug target) methylation (adenine)^a^Indicates possible targets of antiviral compounds

### NSP1 (Leader Protein) {#Sec4}

Nonstructural protein 1 (NSP1) is the first protein of the polyprotein of SARS CoV-2 (Fig. [1](#Fig1){ref-type="fig"}---sequence alignment of NSP1 for SARS CoV with SARS CoV-2). This protein is also known as the leader protein. This protein is also found in SARS coronavirus and is known to be a potent inhibitor of host gene expression. NSP1 binds to the 40S ribosome of the host cell to inactivate translation and promotes host mRNA degradation selectively, while the viral SARS CoV mRNA remain intact \[[@CR15]\]. Figure [1](#Fig1){ref-type="fig"} shows the amino acid sequence alignment for the NSP1 proteins of SARS CoV (from genome: NCBI Reference Sequence: NC_004718.3) and SARS CoV-2.Fig. 1Alignment of the primary amino acid sequence of NSP1 of SARS CoV (top, NP_828860.2) and SARS CoV-2 (YP_009725297.1). Sequence identity: 84.4%. Sequence similarity: 93.9%---determined using LALIGN software (and for subsequent alignments, Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"}, [15](#Fig15){ref-type="fig"}, [16](#Fig16){ref-type="fig"}, [17](#Fig17){ref-type="fig"}, [18](#Fig18){ref-type="fig"}, [19](#Fig19){ref-type="fig"}, [20](#Fig20){ref-type="fig"}, [21](#Fig21){ref-type="fig"}, [22](#Fig22){ref-type="fig"}, [23](#Fig23){ref-type="fig"}, [24](#Fig24){ref-type="fig"}, [25](#Fig25){ref-type="fig"}, and [26](#Fig26){ref-type="fig"}, see Supporting Information for output data) \[[@CR16]\].Fig. 2The primary amino acid sequence alignment of NSP2 for SARS CoV (NP_828861.2) and SARS CoV-2 (YP_009725298.1). These proteins have 68.3% sequence identity (90.0% similar)

### NSP2 {#Sec5}

Nonstructural protein 2 (NSP2) is the second protein of the polyprotein of SARS CoV-2 (Fig. [2](#Fig2){ref-type="fig"}). This protein is conserved in SARS CoV, the related beta coronavirus to SARS CoV-2. In SARS CoV, NSP2 was found to bind to two host proteins: prohibitin 1 and prohibitin 2 (PHB1 and PHB2) \[[@CR17]\]. PHB1 and PHB2 proteins are known to play roles in cell cycle progression, cell migration, cellular differentiation, apoptosis, and mitochondrial biogenesis. The binding of NSP2 to PHB1 and PHB2 proteins suggest that NSP2 plays a role in disrupting the host cell environment.

### NSP3 (Papain like Proteinase) {#Sec6}

NSP3 is the papain-like proteinase protein (Fig. [3](#Fig3){ref-type="fig"}). This protein is nearly 200 kDa in size and is the largest protein (not including the polyproteins ORF1a and ORF1ab) encoded by the coronaviruses. With such a long sequence, it possesses several conserved domains: ssRNA binding, ADPr binding, G-quadruplex binding, ssRNA binding, protease (papain-like protease), and NSP4 binding), and transmembrane domain. Among the 16 nonstructural proteins, NSP3, NSP4, and NSP6 have transmembrane domains \[[@CR18]\]. The papain like protease 1 (PL1 protease) of alpha coronavirus (alpha CoV) Transmissible Gastroenteritis Virus (TGEV), which is part of NSP3, was shown to cleave the site between NSP2 and NSP3. Furthermore, this papain like protease domain is responsible for the release of NSP1, NSP2, and NSP3 from the N-terminal region of polyproteins 1a and 1ab from coronaviruses \[[@CR19]\]. Considering this important protease activity to release essential proteins for viral activity, the inhibition of NSP3 protease activity is an important target for antiviral activity \[[@CR20]\]. Tanshinones, a class of natural products have been found to inhibit NSP3 protease activity.Fig. 3The primary amino acid sequence alignment of NSP3 for SARS CoV (NP_828862.2) and SARS CoV-2 (YP_009725299.1). Sequence identity: 76.0%, sequence similarity: 91.8%

### NSP4 (Contains Transmembrane Domain 2) {#Sec7}

NSP4 interacts with NSP3 and possibly host proteins to confer a role related to membrane rearrangement in SARS CoV. Moreover, the interaction between NSP4 and NSP3 is essential for viral replication \[[@CR18]\]. The sequence alignment for NSP4 proteins for SARS CoV and SARS CoV-2 is shown in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4The primary amino acid sequence alignment of NSP4 for SARS CoV (NP_904322.1) and SARS CoV-2 (YP_009725300.1). Sequence identity: 80.0%, sequence similarity: 95.0%

### NSP5 (3C-like proteinase) {#Sec99}

The NSP5 protein based on the Middle East Respiratory Syndrome (MERS) coronavirus has been characterized. NSP5 cleaves at 11 distinct sites to yield mature and intermediate nonstructural proteins (NSPs) \[[@CR21]\]. The amino acid sequence alignment for NSP5 of SARS CoV and SARS CoV-2 is shown in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5The primary amino acid sequence of NSP5 for SARS CoV (NP_828863.1) and SARS CoV-2 (YP_009725301.1). Sequence identity: 96.1%, sequence similarity: 99.7%

### NSP6 (Putative Transmembrane Domain) {#Sec8}

The NSP6 protein of the avian coronavirus (infectious bronchitis virus, IBV) was shown to generate autophagosomes from the endoplasmic reticulum (ER) (Fig. [6](#Fig6){ref-type="fig"}b shows sequence alignment with SARS CoV-2 NSP6). Autophagosomes facilitate assembly of replicase proteins. Furthermore, NSP6 limited autophagosome/lysosome expansion, which in turn prevents autophagosomes from delivering viral components for degradation in lysosomes \[[@CR22]\]. With SARS CoV, NSP6 was shown to induce membrane vesicles \[[@CR23]\]. The amino acid sequence alignment for NSP6 of SARS CoV and SARS CoV-2 is shown in Fig. [6](#Fig6){ref-type="fig"}.Fig. 6Amino acid sequence alignment between the NSP6 proteins of SARS CoV (top: NP_828864.1) and SARS-CoV-2 (bottom: YP_009725302.1). Sequence identity: 88.2%, sequence similarity: 98.3%

### NSP7 {#Sec9}

NSP7 is required to form a complex with NSP8 (next section) and NSP12 to yield the RNA polymerase activity of NSP8 \[[@CR24]\]. The primary amino acid sequence alignment for the NSP8 proteins for SARS CoV and SARS CoV-2 is shown in Fig. [7](#Fig7){ref-type="fig"}. Only one amino acid residue is different (arginine vs. lysine) but the charge is conserved at this location.Fig. 7The primary amino acid sequence alignment of NSP7 SARS CoV (NP_828865.1) and SARS CoV-2 (YP_009725303.1). Sequence identity: 98.8%, sequence similarity: 100%

### NSP8 {#Sec10}

NSP8 is a peptide cofactor that makes a heterodimer with NSP7 (the other peptide cofactor), and this NSP7-NSP8 heterodimer complexes with NSP12. In addition to the NSP7-NSP8 heterodimer, an NSP8 monomer unit also complexes with NSP12, which ultimately forms the RNA polymerase complex. The cryo-EM structure of this complex has been solved \[[@CR25]\]. The amino acid sequence alignment for NSP8 of SARS CoV and SARS CoV-2 is shown in Fig. [8](#Fig8){ref-type="fig"}.Fig. 8The primary amino acid sequence alignment of NSP8 for SARS CoV (NP_828866.1) and SARS CoV-2 (YP_009725304.1). Sequence identity: 97.5%, sequence similarity: 100.0%

### NSP9 {#Sec11}

NSP9 from the porcine reproductive and respiratory syndrome virus (PRRSV) has been found to interact with the DEAD-box RNA helicase 5 (DDX5) cellular protein \[[@CR26]\]. This interaction between NSP9 and DDX5 has been shown to be important for viral replication---when the DDX5 gene was silenced in MARC-145 cells, the virus titers were lower by tenfold. Figure [9](#Fig9){ref-type="fig"} shows the amino acid sequence alignment between the two NSP9 proteins from SARS CoV and SARS CoV-2.Fig. 9The primary amino acid sequence alignment of NSP9 for SARS CoV (NP_828868.1) and SARS CoV-2 (YP_009725305.1). Sequence identity: 97.3%, sequence similarity: 99.1%

### NSP10 {#Sec12}

NSP10 has been shown to interact with NSP14 in SARS coronavirus, and this interaction stimulates activity of NSP14. NSP 14 is known to function as an S-adenosylmethionine (SAM)-dependent (guanine-N7) methyl transferase (N7-MTase) \[[@CR27]\]. Furthermore, NSP10 has also been shown to stimulate the activity of NSP16, which is a 2′-O-methyltransferase \[[@CR28]\]. Figure [10](#Fig10){ref-type="fig"} shows the amino acid sequence alignment between the two NSP10 proteins from SARS CoV and SARS CoV-2.Fig. 10The primary amino acid sequence alignment of NSP10 for SARS CoV (NP_828868.1) and SARS CoV-2 (YP_009725306.1). Sequence identity: 97.1%, sequence similarity: 99.3%

### NSP11 {#Sec13}

The function of NSP11 seems to be unknown. NSP11 is made of thirteen amino acids and the first nine amino acids (sadaqsfln) are identical to the first nine in NSP12. Figure [11](#Fig11){ref-type="fig"} shows the amino acid sequence alignment between the two NSP12 proteins from SARS CoV and SARS CoV-2.Fig. 11The primary amino acid sequence alignment of NSP11 for SARS CoV (NP_904321.1) and SARS CoV-2 (YP_009725312.1). Sequence identity: 84.6%, sequence similarity: 100.0%

### NSP12 (RNA Dependent RNA Polymerase) {#Sec14}

NSP12 is the RNA-dependent RNA polymerase that copies viral RNA. As mentioned, NSP12 makes a complex with an NSP7-NSP8 heterodimer and an NSP8 monomer to confer processivity of NSP12. NSP12 exhibits poor processivity in RNA synthesis---that is the presence of NSP7 and NSP8 lowers the dissociation rate of NSP12 from RNA \[[@CR29]\]. The amino acid sequence alignment between the two NSP12 proteins from SARS CoV and SARS CoV-2 is shown in Fig. [12](#Fig12){ref-type="fig"}.Fig. 12The primary amino acid sequence alignment of NSP12 for SARS CoV (NP_828869.1) and SARS CoV-2 (YP_009725307.1). Sequence identity: 96.4%, sequence similarity: 99.4%

### NSP13 (Helicase) {#Sec15}

SARS CoV was used to characterize the helicase enzyme, NSP13, which unwinds duplex RNA \[[@CR30]\]. The crystal structure of NSP13 of SARS CoV has been reported \[[@CR31]\]. Furthermore, it has been shown that binding of NSP12 with NSP13 can enhance the helicase activity of NSP13. In addition to its helicase activity, NSP13 of SARS CoV is also known to possess 5′-triphosphatase activity, which is responsible for introducing the 5′-terminal cap of the viral mRNA \[[@CR32]\]. Both eukaryotic and most viral mRNA have a 5′-terminal cap structure: m7G(5)ppp(5)N-. This 5′-terminal cap is the site of recognition for translation and plays a role in splicing, nuclear export, translation, and stability of mRNA. This process of incorporating the 5′-terminal cap will be discussed in the next section: (xiv) NSP14. The sequence alignment for NSP13 of SARS CoV and SARS CoV-2 is shown in Fig. [13](#Fig13){ref-type="fig"}. Interestingly, only one amino acid residue is different out of the 601 amino acids in these two proteins (isoleucine vs. valine).Fig. 13The primary amino acid sequence of NSP13 SARS CoV (NP_828870.1) and SARS CoV-2 (YP_009725308.1). Sequence identity: 99.8%, sequence similarity: 100.0%

### NSP14 (3′ to 5′ Endonuclease, N7-Methyltransferase) {#Sec16}

NSP14 from coronavirus is known to have 3′-5′ exoribonuclease activity and N7-methyltransferase activity \[[@CR33]\]. The guanine-N7-methyltransferase activity is part of the process for introducing the 5′-cap of the virus, which involves multiple steps: \[[@CR1]\] the gamma-phosphate of the 5′end of nascent mRNA is removed by the RNA triphosphatase (NSP13), \[[@CR32]\], \[[@CR2]\] a GMP moiety derived from a covalent enzyme-GMP intermediate is transferred to the resulting mRNA with a diphosphate end, \[[@CR3]\] the GpppA cap is methylated with S-adenosyl-methionine, which is catalyzed by the guanine-N7-methyltransferase (NSP14) to yield the cap-0 structure, \[[@CR34]\] and \[[@CR4]\] 2′-O-methylation by NSP16 of adenine gives the cap-1 structure \[[@CR35]\]. It is currently unknown which enzyme incorporates the GMP group involved in the second step, and it is possible that the virus uses the host guanylyltransferase enzyme \[[@CR36]\]. Figure [14](#Fig14){ref-type="fig"} shows the amino acid sequence alignment between the NSP14 proteins of SARS CoV and SARS CoV-2.Fig. 14The primary amino acid sequence alignment of NSP14 of SARS CoV (NP_828871.1) and SARS CoV-2(YP_009725309.1). Sequence identity: 95.1%, sequence similarity: 99.1%

### NSP15 (endoRNAse) {#Sec17}

NSP15 of SARS coronavirus has been biochemically characterized as an endoribonuclease that cleaves RNA at uridylates at the 3′-position to form a 2′-3′ cyclic phosphodiester product \[[@CR37]\]. The NSP15 protein specifically targets and degrades the viral polyuridine sequences to prevent the host immune sensing system from detecting the virus \[[@CR38]\]. The crystal structure of NSP15 has been reported for SARS CoV \[[@CR39]\] and SARS CoV-2 \[[@CR40]\]. NSP15 uses manganese as a cofactor to promote endoribonuclease activity \[[@CR41]\]. It has been suggested that NSP15 degrades viral dsRNA to prevent host recognition \[[@CR42]\]. The amino acid sequence alignment of NSP15 from SARS CoV and SARS CoV-2 is shown in Fig. [15](#Fig15){ref-type="fig"}.Fig. 15The primary amino acid sequence alignment of NSP15 of SARS CoV (NP_828872.1) and SARS CoV-2 (YP_009725310.1). Sequence identity: 88.7%, sequence similarity: 97.7%

### NSP16 (2′-O-Ribose-Methyltransferase) {#Sec18}

NSP16 for coronavirus has been biochemically \[[@CR43]\] (feline coronavirus, FCoV) and structurally \[[@CR44]\] (complex of NSP10-NSP16 for SARS CoV) characterized. The viral RNA has a 5′-cap, which protects it from mRNA degradation by 5′-exoribonucleases, promotes mRNA translation, and prevents the viral RNA from being recognized by innate immunity mechanisms \[[@CR44]\]. The RNA cap is an N7-methylated guanine nucleotide connected through a 5′-5′ triphosphate bridge to the first transcribed nucleotide (adenine). NSP16 methylates the 2′-hydroxy group of adenine using S-adenosylmethionine as the methyl source. Figure [16](#Fig16){ref-type="fig"} shows the amino acid sequence alignment between the two NSP16 proteins from SARS CoV and SARS CoV-2.Fig. 16The primary amino acid sequence alignment of NSP16 of SARS CoV (NP_828873.2) and SARS CoV-2 (YP_009725311.1). Sequence identity: 93.3%, sequence similarity: 99.0%

Spike Protein (Surface Glycoprotein) {#Sec19}
------------------------------------

The spike protein (Fig. [17](#Fig17){ref-type="fig"}---sequence alignment between SARS CoV and SARS CoV-2) is a glycoprotein, which mediates attachment of the virus to the host cell. The structure of the spike (S) protein has been determined. This protein recognizes the human angiotensin-converting enzyme 2 (ACE2) protein on the host cell surface \[[@CR45]--[@CR47]\]. SARS CoV spike mouse polyclonal antibodies potently inhibited SARS CoV-2 spike protein mediated entry into cells \[[@CR47]\]. Interestingly, a furin cleavage site (highlighted in Fig. [17](#Fig17){ref-type="fig"}: QTQTNSPRRARSVASQSIIA) was located in the S protein of SARS CoV-2, which was lacking in the S protein of SARS CoV. This difference in site could possibly explain the difference in pathogenicity of these two viruses \[[@CR47]\].Fig. 17The primary amino acid sequence alignment of the spike proteins from SARS CoV (NP_828851.1) and SARS CoV-2 (BCA87361.1). Sequence identity: 76.0%, sequence similarity: 91.5%

ORF3a Protein {#Sec20}
-------------

The ORF3a protein from SARS CoV is an ion channel protein related to NLRP3 inflammasome activation. ORF3a interacts with TRAF3, which in turn activates ASC ubiquitination, and as a result, leads to activation of caspase 1 and IL-1β maturation \[[@CR48]\]. The amino acid sequence alignment between the two ORF3a proteins from SARS CoV and SARS CoV-2 is shown in Fig. [18](#Fig18){ref-type="fig"}.Fig. 18The primary amino acid sequence alignment of the ORF3a proteins from SARS CoV (NP_828852.2) and SARS CoV-2 (BCA87362.1). Sequence identity: 72.4%, sequence similarity: 90.2%

Envelope Protein {#Sec21}
----------------

The envelope protein is a small integral membrane protein in coronaviruses, which can oligomerize and create an ion channel \[[@CR49]\]. The four structural proteins of coronaviruses are: S protein, M protein, E protein, and N protein \[[@CR50]\]. The E protein has been shown to play multiple roles in the viral replication cycle: \[[@CR1]\] viral assembly, \[[@CR51]\] \[[@CR2]\] virion release, \[[@CR52]\] and \[[@CR3]\] viral pathogenesis \[[@CR53]\]. Interestingly, in the sequence alignment of the E proteins from SARS CoV and SARS CoV-2 (Fig. [19](#Fig19){ref-type="fig"}), there is a glutamate residue (E69) with a negative charge in SARS CoV that corresponds to a positively charged arginine in SARS CoV-2 (R69).Fig. 19The primary amino acid sequence of the E proteins (ORF4) from SARS CoV (NP_828854.1) and SARS CoV-2 (BCA87363.1). Sequence identity: 94.7%, sequence similarity: 97.4%

Membrane Protein {#Sec22}
----------------

The SARS coronavirus membrane (M) protein is an integral membrane protein that plays an important role in viral assembly \[[@CR54]\]. In addition, the SARS coronavirus M protein has been shown to induce apoptosis \[[@CR55]\]. The M protein interacts with the nucleocapsid (N) protein to encapsidate the RNA genome \[[@CR56]\]. Figure [20](#Fig20){ref-type="fig"} shows the amino acid sequence alignment of the two ORF5 proteins from SARS CoV and SARS CoV-2.Fig. 20The primary amino acid sequence of the M proteins (ORF5) from SARS CoV (NP_828855.1) and SARS CoV-2 (BCA87364.1). Sequence identity: 90.5%, sequence similarity: 98.2%

ORF6 Protein {#Sec23}
------------

The ORF6 protein from SARS coronavirus is an accessory protein that plays an important role in viral pathogenesis \[[@CR57], [@CR58]\]. Using a yeast two-hybrid system, ORF6 was shown to interact with NSP8, the nonstructural protein related to promoting RNA polymerase activity \[[@CR57]\]. Figure [21](#Fig21){ref-type="fig"} shows the amino acid sequence alignment of the two ORF6 proteins from SARS CoV and SARS CoV-2.Fig. 21The primary amino acid sequence alignment of the ORF6 proteins from SARS CoV (NP_828856.1) and SARS CoV-2 (BCA87365.1). Sequence identity: 68.9%, sequence similarity: 93.4%

ORF7a Protein {#Sec24}
-------------

ORF7a from SARS coronavirus is an accessory protein that is a type I transmembrane protein and its crystal structure has been determined \[[@CR59]\]. Figure [22](#Fig22){ref-type="fig"} shows the amino acid sequence alignment between the two ORF7a proteins of SARS CoV and SARS CoV-2.Fig. 22The primary amino acid sequence of the ORF7a protein from SARS CoV (NP_828857.1) and SARS CoV-2 (BCA87366.1). Sequence identity: 85.2%, sequence similarity: 95.9%

ORF7b Protein {#Sec25}
-------------

The ORF7b accessory protein from SARS coronavirus is localized in the Golgi compartment \[[@CR60]\]. Figure [23](#Fig23){ref-type="fig"} shows the sequence alignment between the two ORF7b proteins of SARS CoV and SARS CoV-2.Fig. 23The primary amino acid sequence of the ORF7b proteins from SARS CoV (NP_849175.1) and SARS CoV-2 (BCB15096.1). Sequence identity: 85.4%, sequence similarity: 97.2%

ORF8 Protein {#Sec26}
------------

SARS CoV-2 has a single ORF8 protein while SARS CoV has two ORF8 proteins: ORF8a and ORF8b \[[@CR61]\]. In SARS CoV, the ORF8b protein binds to the IRF association domain (IAD) region of interferon regulatory factor 3 (IRF3), which in turn inactivates interferon signaling \[[@CR62]\]. Interestingly, L84S and S62L missense mutations have been reported in various SARS CoV-2 sequences \[[@CR5]\]. Figure [24](#Fig24){ref-type="fig"} shows the alignment between the ORF8 protein of SARS CoV-2 with the ORF8a and ORF8b proteins of SARS CoV.Fig. 24Sequence alignment of ORF8a (NP_849176.1) and ORF8b (NP_849177.1) proteins from SARS CoV (top and middle) with the ORF8 protein (QJA17759.1) from SARS CoV-2 (bottom). Sequence identity and sequence similarity between ORF8a (SARS CoV) and ORF8 (SARS CoV-2): 31.7% and 70.7% in 41 amino acid overlap. Sequence identity and sequence similarity between ORF8b (SARS CoV) and ORF8 (SARS CoV-2): 40.5% and 66.7% in 42 amino acid overlap

Nucleocapsid Protein {#Sec27}
--------------------

The nucleocapsid (N) protein of coronaviruses is a structural protein that binds directly to viral RNA and providing stability \[[@CR63]\]. Furthermore, the N protein of SARS CoV-2 (Fig. [24](#Fig24){ref-type="fig"}) has been found to antagonize antiviral RNAi \[[@CR64]\]. In another study, the nucleocapsid protein of SARS CoV was found to inhibit the activity of cyclin-cyclin-dependent kinase (cyclin-CDK) complex. Inactivation of the cyclin-CDK complex results in hypophosphorylation of the retinoblastoma protein and in turn inhibits S phase (genome replication) progression in the cell cycle \[[@CR65]\]. Figure [25](#Fig25){ref-type="fig"} shows the amino acid sequence alignment between the two N proteins of SARS CoV and SARS CoV-2.Fig. 25The primary amino acid sequence of the N protein from SARS CoV (ORF9a, NP_828858.1) and SARS CoV-2 (ORF9, BCA87368.1). Sequence identity: 90.5%, sequence similarity: 97.2%

ORF10 Protein {#Sec28}
-------------

ORF10 protein from SARS CoV-2 is comprised of 38-amino acids and its function is unknown. Interestingly, SARS CoV possesses an ORF9b protein (NP_828859.1), which is not present in SARS CoV-2. Figure [26](#Fig26){ref-type="fig"} shows the sequence alignment between ORF10 of SARS CoV-2 with ORF9b of SARS CoV. SARS CoV-2 does not have an ORF10 protein. A summary of the sequence identities and similarities of the discussed proteins from SARS CoV and SARS CoV-2 is shown in Table [4](#Tab3){ref-type="table"}.Fig. 26The primary amino acid sequence alignment of the ORF9b protein from SARS CoV and the ORF10 protein from SARS CoV-2 (Accession number: BCA87369.1). Sequence identity: 28.6%, sequence similarity: 52.4%Table 4Sequence identity and similarities between SARS CoV-2 proteins and SARS CoV proteins determined through LALIGN (17) (see Supporting Information)EntryProteinAmino acid overlapSequence identitySequence similarity1NSP118084.4%93.4%2NSP263868.3%90.0%3NSP31,95276.0%91.8%4NSP450080.0%95.0%5NSP530696.1%99.7%6NSP628788.2%98.3%7NSP78398.8%100.0%8NSP819897.5%100.0%9NSP911397.3%99.1%10NSP1013997.1%99.3%11NSP111384.6%100.0%12NSP1293296.4%99.4%13NSP1360199.8%100.0%14NSP1452795.1%99.1%15NSP1534688.7%97.7%16NSP1629893.3%99.0%17S protein1,27776.0%91.5%18ORF3a1,38172.4%90.2%19E Protein7694.7%97.4%20M Protein22290.5%98.2%21ORF66168.9%93.4%22ORF7a12285.2%95.9%23ORF7b4185.4%92.7%24a(ORF8 vs 8a)^a^4131.7%70.7%24b(ORF8 vs 8b)^a^4240.5%66.7%25N Protein42290.5%97.2%26(ORF10 vs 9b)^a^2128.6%52.4%^a^(SARS CoV-2 protein vs SARS CoV protein). Other reports have also reported amino acid sequence identities using different algorithms (3,67)

Overlapping Genes: ORF9b and Two Proteins with Variation Among SARS CoV-2 Sequences: ORF3b and ORF9c {#Sec29}
====================================================================================================

Overlapping genes in coronavirus have been previously observed \[[@CR67]\]. For example, in SARS CoV, the start and end positions in the nucleotide sequence of the N-protein are 28,120 and 29,388 respectively while the ORF9b gene of SARS CoV starts and ends at positions: 28,130 and 28,426 (within the gene sequence of the N-protein) \[[@CR68]\]. Similarly, there is a putative ORF9b protein in SARS CoV-2 located within the gene encoding the N-protein, which does not yet have an accession number \[[@CR4]\].

In the gene alignment of 2,784 SARS CoV-2 sequences, two variations were recognized in the SARS CoV-2 genome \[[@CR66]\]. It was recognized that a premature stop codon at position 14 of ORF3b in SARS CoV-2 in 17.6% of isolates (position E14). Furthermore, there were two mutations that gave rise to premature stop codons in ORF9c (at position Q41 in 0.7% of sequences and at position Q44 in 1.4% of the sequences). The observations of these stop codons suggested that these genes for ORF3b and ORF9c may not be bonafide gene sequences in SARS CoV-2. With the putative SARS CoV-2 ORF3b protein, only 12 out of 57 overlapping amino acid residues were identical (21% sequence identity) to the ORF3b protein of SARS CoV \[[@CR3]\]. In the above sections, ORF3b and ORF9c for SARS CoV-2 were not included in the above analysis. Another protein lacking an accession number is ORF14 \[[@CR69]\].

Nontranslated (or Untranslated) Regions of SARS CoV-2 Genome {#Sec30}
============================================================

Considering the locations of each gene presented in Table [1](#Tab1){ref-type="table"}, there are regions of the genome that are not translated into proteins, which is related to the non-canonical translational strategy employed by this virus \[[@CR70]\]. The nucleotide sequences between the genes are the intergenic regions \[[@CR71]\]. For instance, there is a conserved transctiption regulatory sequence (TRS) -- a conserved hexanucleotide sequence: (5′-ACGAAC-3′) \[[@CR71]\] that could be found in between some of the open reading frames (Table [5](#Tab4){ref-type="table"}, Entries 2, 3, 4, 5, 7, and 9). This particular sequence has previously been identified as the leader-body fusion sites \[[@CR71]\]. Furthermore, this sequence is a conserved motif that can be found in subgroup 2b, 2c, and 2d viruses \[[@CR72]\]. Another transcriptional regulatory sequence was CUAAAC (e.g. Table [5](#Tab4){ref-type="table"}, Entry 1) \[[@CR73], [@CR74]\].Table 5Nontranslated RNA sequence of SARS CoV-2 (NCBI Reference Sequence: NC_045512.2)EntryLocation (position)Sequence1Beginning-ORF1ab (1--265)1 auuaaagguu uauaccuucc cagguaacaa accaaccaac uuucgaucuc uuguagaucu61 guucucuaaa cgaacuuuaa aaucugugug gcugucacuc ggcugcaugc uuagugcacu121 cacgcaguau aauuaauaac uaauuacugu cguugacagg acacgaguaa cucgucuauc181 uucugcaggc ugcuuacggu uucguccgug uugcagccga ucaucagcac aucuagguuu241 cguccgggug ugaccgaaag guaag2ORF1ab-ORF2 (21,556--21,562)1 acgaaca3ORF2-ORF3a (25,385--25,392)1 acgaacuu4ORF3a-ORF4 (26,221--26,244)1 gcacaagcug augaguacga acu5ORF4-ORF5 (26,473--26,522)1 acgaacuaaa uauuauauua guuuuucugu uuggaacuuu aauuuuagcc6ORF5-ORF6 (27,192--27,201)1 gugacaacag7ORF6-ORF7a (27,388--27,393)1 acgaac8ORF7b-ORF8 (27,888--27,893)1 acgaac9ORF8-ORF9 (28,260--28,273)1 acgaacaaac uaaa10ORF9-ORF10 (29,534--29,557)1 acucaugcag accacacaag gcag11ORF10-end (29,675--29,903)1 caaucuuuaa ucagugugua acauuaggga ggacuugaaa gagccaccac auuuucaccg61 aggccacgcg gaguacgauc gaguguacag ugaacaaugc uagggagagc ugccuauaug121 gaagagcccu aauguguaaa auuaauuuua guagugcuau ccccauguga uuuuaauagc181 uucuuaggag aaugacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa

Exploration of Treatment Options for COVID-19 {#Sec31}
=============================================

An intense effort has been put forth to discover potential treatment options for COVID-19, the disease caused by SARS CoV-2 \[[@CR75]--[@CR77]\]. For instance, the FDA approved drug, ivermectin, is known to inhibit nuclear transport, and has been shown to inhibit the replication of SARS CoV-2 \[[@CR78]\]. Other drugs have been repurposed and tested against COVID-19 \[[@CR79], [@CR80]\]. Remdesivir is a potential antiviral drug originally developed to treat ebola \[[@CR81]\] and has been used to treat COVID-19 \[[@CR82]\] by inhibiting viral RNA polymerase activity. Hydroxychloroquine \[[@CR83]\] and chloroquine \[[@CR84]\] have been used to potentially treat COVID-19. However, the use of these drugs has been known to result in cardiotoxicity \[[@CR85], [@CR86]\]. In fact, in a recent observational study, it was determined that hydroxychloroquine administration was not associated with a greatly lowered risk of death from COVID-19 \[[@CR87]\].

A recent study identified 332 human proteins that interact with SARS CoV-2 proteins \[[@CR66]\]. In this report, the predicted SARS CoV-2 proteins (NSPs 1--16 and ORFs) were expressed with 2xstreptavidin affinity tags. These tagged SARS CoV-2 proteins were expressed in human embryonic kidney (HEK)293T/17 cells and isolated the viral protein-(human protein) interactions using affinity purification-mass spectrometry. A total 332 protein--protein interactions (PPIs between SARS CoV-2 proteins and human proteins) were identified. Of these PPIs, 66 of them are targetable by compounds. Table [6](#Tab5){ref-type="table"} shows a set of compounds that target the identified PPIs based on chemoinformatics (entries 1--28) or expertise knowledge (entries 29--44). From the subset of potential antiviral compounds that were tested, two classes of compounds were found to be effective against viral pathogenesis: \[[@CR1]\] protein translation inhibitors (i.e. zotatifin, ternatin-4, and PS3061), and \[[@CR2]\] Sigma1 and Sigma2 receptor ligands (i.e. approved drugs: clemastine, cloperastine, and progesterone and PB28, which was \~ 20 times more potent than hydroxychloroquine with an IC~90~ of 280 nM in the viral titer assay is undergoing pre-clinical trials for anti-cancer \[[@CR88]\] activity).Table 6Drugs that potentially target (modulate) proteins that interact with SARS CoV-2 proteins as described in reference \[[@CR66]\]EntryViral Protein-(Human Gene)Compound Name(s)1E protein-(BRD2/4)JQ1,^a^ RVX-208^b^2N protein-(CSNK2A2)Silmitasertib (cancer),^c^ TMCB^a^3NSP5-(HDAC2)Apicidin,^a^ Valproic acid (CNS disease, cancer)^c^4NSP6-(ATP6AP1)Bafilomycin A1^a^5NSP6-(SIGMAR1)E-52862,^b^ PD-144418,^a^ RS-PPCC,^a^ PB28,^a^Haloperidol (CNS disease)^c^6NSP6-(SLC6A15)Loratadine (antihistamine)^3^7ORF9C-(TMEM97)PB28,^a^ haloperidol (CNS disease)^c^8M protein-(ATP6V1A)Bafilomycin A1^a^9NSP7-(COMT)Entacapone (Parkinson's disease)^c^10NSP7-(PTGES2)Indomethacin (inflammation/pain)^c^11NSP7-(NDUFs)Metformin (diabetes)^c^12ORF9C-(NDUFs)Metformin^c^13NSP12-(RIPK1)Ponatinib (cancer)^c^14NSP13-(PRKACA)H-89^a^15NSP14-(IMPDH2)Merimepodib^b^16NSP14-(GLA)Migalastat (Fabry disease)^c^17NSP14-(IMPDH2)Mycophenolic acid (organ rejection),^3^ ribavirin (virus)^c^18ORF8-(DNMT1)Azacitidine^c^19ORF8-(LOX)CCT 365623^a^20ORF9b-(MARK2/3)Midostaurin,^3^ Ruxolitinib^c^21ORF9b-(DCTPP1)ZINC1775962367,^a^ ZINC4326719,^a^ ZINC4511851^a^22ORF9b/NSP13-(MARK3/TBK1)ZINC95559591^a^23ORF9C-(F2RL1)AC-55541,^a^ AZ8838^a^24ORF9C-(ABCC1)Daunorubicin^c^25ORF9C-(F2RL1)GB110^a^26ORF9C-(ABCC1)S-Verapamil (hypertension)^c^27ORF9C-(F2RL1)AZ3451^a^28M-Protein-(SLC1A3)UCPH-101^a^29E protein-(BRD2/4)ABBV-744,^b^ dBET6,^a^ MZ1,^a^ CPI-0610^b^30N protein-(LARP1)Sapanisertib,^b^ Rapamycin (organ rejection)^c^31NSP2-(FKBP15)Rapamycin^c^32ORF8-(FKBP7/10)Rapamycin^c^33NSP2-(EIF4E2/H)Zotatifin^b^34ORF10-(VCP)CB5083^b^35NSP6-(SIGMAR1)Chloroquine (malaria)^c^36NSP9-NEK9Dabrafenaib (cancer)^c^37NSP13-CEP250WDB002^b^38NSP14-IMPDH2Sanglifehrin A^a^39ORF8-(FKBP7)FK-506 (organ rejection)^c^40ORF8-(FKBP10)FK-506^c^41ORF10-(CUL2)Pevonedistat^b^42ORF10-(VCP)DBeQ, ML240^a^43ORF8-(PLOD1/2)Minoxidil (hair loss)^c^44NSP4/9/ORF6-(NUPs RAE1)Selinexor (cancer)^c^Entries 1--28 were determined from chemoinformatics. Entries 29--44 were determined from specialist knowledge^a^Pre-clinical^b^Clinical trial^c^FDA-approved drug. In parentheses after the drug is what the FDA-approved drug is used to treat in the clinic

Moreover, in another collaborative study, a library of 12,000 FDA-approved or clinical-stage drugs were tested against SARS CoV-2 infection in Vero-E6 (African green monkey kidney) cells \[[@CR89]\]. Some effective compounds identified in the screen were: PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors (MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334), and MLN-3897 (a CCR1 antagonist).

Traditional Chinese Medicine (TCM) has also been employed in China to treat COVID-19 \[[@CR90]\]. However, due to potential toxic components present in TCM remedies, \[[@CR91], [@CR92]\] the use of this strategy should be handled with caution \[[@CR93]\]. Ironically, it has been suggested that TCM could have potentially been the cause of COVID-19 \[[@CR94]\].

In addition to small molecules, vaccines are also currently being developed against SARS CoV-2, \[[@CR95]\] and convalescent plasma transfusions have been used to treat COVID-19 \[[@CR96]\]. Nevertheless, more research is needed to develop effective treatments against SARS CoV-2 especially in the context of future outbreaks \[[@CR97], [@CR98]\].

Conclusion {#Sec32}
==========

Although there is some variation in sequence in the proteins, many of the proteins found in SARS CoV-2 (NC_045512.2) are also found in SARS CoV (AY515512.1 or NC_004718.3) with 77.1% of the protein sequences shared in their proteomes \[[@CR99]\]. Thus, previous research on related coronavirus proteins enable a better understanding of how we can approach to understand the current coronavirus (SARS CoV-2) that caused the current global pandemic (COVID-19). The general structures of most of the proteins from SARS CoV-2 can be visualized from homology models \[[@CR100]\]. Advances in the knowledge of the structures and functions of the proteins in SARS CoV-2 will enable researchers to design better antiviral drugs that target this virus.
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